FDA Updates Darunavir Tablet and Oral Suspension Labeling with Pediatric Dosing Information

“On February 1, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to include once daily dosing in treatment-naïve subjects 3 to less than 18 years of age and once daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.” The updated labeling will be available at the FDA website. More information is available: FDA: Press release AIDSinfo: Darunavir (Prezista) patient drug summary